ISRG Q3 2026 Earnings Analysis
Q3 revenue grew 22% to $3B on 546 system placements (+28%) and 15% procedure growth; 3-5% pricing cuts for benign procedures; Malaysia facility planned for 2028.
Key Metrics
要点总结
- Q3 revenue grew 22% to $3B; 546 da Vinci placements (+28%); total procedures up 15% (da Vinci +14%, Ion +31%).
- Pricing actions reduce I&A revenue 3-5% starting 2027 via extended-use instruments for high-volume benign procedures.
- $450M litigation settlement reached for third-party servicing; new Malaysia facility planned to begin operations 2028.
收听平台
可用语言
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.
And I'm Jordan. Today we're diving into Intuitive Surgical's Q3 2026 results — the robotic surgery giant behind the da Vinci system.
Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good to have that out of the way. And Alex, this was a packed quarter — big numbers, a major legal settlement, pricing strategy shifts, even a new factory announcement in Malaysia.
Let's start with the headline numbers. Revenue grew 22% year-over-year to just over $3 billion, with 84% of that being recurring revenue — which, as always, is the magic of Intuitive's razor-and-blade business model.
Right, and non-GAAP EPS grew 25% to $3 per share. Operating margin came in at 42%, or 41% if you strip out a one-time tariff refund. That's genuinely elite profitability for medtech.
But here's the asterisk — GAAP net income actually fell to $523 million, down from $704 million a year ago. Why the disconnect?
That's the $450 million litigation settlement. Intuitive reached a no-fault agreement with customers in a class action lawsuit over third-party instrument remanufacturing and servicing. It's subject to court approval, expected sometime next year, but they took the charge now.
So basically, they're paying to put a messy legal issue behind them and get certainty on how they work with hospitals going forward.
Exactly — CEO Dave Rosa framed it as removing a distraction so they can focus on advancing product safety and quality rather than litigating.
Let's talk procedures, because that's really the heartbeat of this business. Total procedures grew 15%, da Vinci procedures up 14%, and Ion — that's their lung biopsy platform — up a blazing 31%.
The geographic split is interesting too. International da Vinci growth was 20%, while U.S. growth was 10% — and that 10% actually drew some pointed analyst questions on the call.
Yeah, an analyst from Wells Fargo flagged that 10% as the slowest U.S. growth since COVID. What was management's response?
Dave Rosa basically said: don't panic, it's a tough comp — last year's Q3 grew 16%, their hardest comparison of the year. CFO Jamie Samath added more color, saying they're leaning into four growth levers: adding system capacity, especially for benign general surgery; pushing into ambulatory surgery centers, where ASC placements doubled over just two quarters; developing cardiac and breast procedures as emerging categories; and new indications in the R&D pipeline.
And speaking of placements — system placements overall were strong. 546 da Vinci systems placed globally, up 28%. The da Vinci 5, their newest platform, now makes up 65% of global placements combined with the single-port system.
They've crossed 2,000 da Vinci 5 systems installed worldwide, used by over 18,000 surgeons. That's real traction for a platform that's still relatively new.
Now let's get into the pricing story, because this is a genuine strategic shift. Intuitive announced they're cutting instrument pricing on high-volume "benign" procedures — think hernia repairs, gallbladder removals, hysterectomies — stuff where laparoscopy has dominated because it's cheaper.
They're extending the useful life of certain instruments and introducing volume-based pricing starting in 2027. The expected impact is a 3% to 5% reduction in da Vinci instrument-and-accessory revenue per procedure once fully rolled out.
That sounds like a headwind, but management was pretty clear this is intentional — they're trading near-term revenue per procedure for long-term volume growth.
Right, and there's precedent. Their first extended-use program back in 2020 had a bigger impact — around 7% — and it successfully drove adoption. Management says this time the hit is smaller, and they expect offsetting tailwinds from things like Force Feedback instrumentation, single-port procedures, and da Vinci 5's integrated insufflation — all of which carry higher revenue per procedure.
There's also a China-specific wrinkle — a policy-driven price cut hitting in November due to local reimbursement code changes.
China's been a tough market generally — Dave Rosa called the operating environment there "challenging" due to tender volumes and competitive intensity. That's offset somewhat by strength in India, which hit 200,000 cumulative procedures with 42% growth, and Japan, which is responding well to reimbursement changes from June.
Let's touch on the Malaysia announcement — they're building a new manufacturing facility in Penang to support long-term Asian demand, expected operational by 2028.
That's a clear signal they're playing a long game internationally, especially outside the U.S., where benign procedure adoption is accelerating fast — up 41% this quarter versus 34% just two quarters ago.
There was also a really compelling clinical data point — the "benign COMPARE" study, a massive meta-analysis covering over 1.5 million da Vinci patients. It showed 54% lower odds of converting to open surgery compared to laparoscopy, and significantly better outcomes versus open surgery across the board.
That's the kind of evidence hospitals need to justify adopting robotics for routine, high-volume procedures — not just complex cancer surgeries. It directly supports the pricing strategy we just talked about.
One more thing worth flagging — share buybacks. Intuitive repurchased $2.9 billion of stock this quarter at an average price of $377. That's a massive capital return move.
It brought their cash pile down from $8.6 billion to $6.8 billion, but shows real confidence from management in the stock's long-term value.
So, bottom line for investors — what's the takeaway here?
I'd frame it as: strong core business, smart long-term positioning, but a couple of things to watch — U.S. procedure growth deceleration, even if it's comp-driven, and the multi-year pricing headwind that's intentional but still a headwind. Management's guiding full-year da Vinci procedure growth to 14-15%, narrowed from their prior range, with gross margin expected between 68.7% and 69.3%.
And before we wrap, Jordan, the obligatory reminder.
Right — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Looking ahead, it seems like Intuitive is making a deliberate bet: trade a little revenue per procedure now to unlock a much bigger addressable market later, especially in benign surgery and international markets.
It's a classic "give up margin to gain volume" playbook — and given their track record with the 2020 program, investors seem willing to give them the benefit of the doubt.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time for another earnings breakdown.
See you next quarter!